MTOR and lymphoma: This dual blockade leads to a metabolic crisis that cannot be tolerated by lymphoma cells, which holds a promise to resolve the issues related to acquired resistance and metabolic rewiring associated with the current therapies targeting the PI3K/AKT/mTOR pathway.